Literature DB >> 9596664

Plasmin can reduce the function of human beta2 glycoprotein I by cleaving domain V into a nicked form.

N Ohkura1, Y Hagihara, T Yoshimura, Y Goto, H Kato.   

Abstract

beta2-Glycoprotein I (beta2GPI) is a highly glycosylated plasma protein with the ability to bind negatively charged substances such as DNA, heparin, dextran sulfate, and negatively charged phospholipids. The most relevant physiological role of beta2GPI is supposed to be the regulation of the function of anionic phospholipids like cardiolipin (CL). beta2GPI consists of a single polypeptide chain (326 amino acid residues) with a molecular mass of about 50 kD and with five tandem repeated domains (I, II, III, IV, and V). In the previous study, we found that factor Xa can produce the nicked form by cleaving Lys 317-Thr 318, using recombinant human domain V (r-Domain V). However, the reaction was extremely slow. In the present paper, we found that plasmin can produce the nicked form of domain V, using recombinant domain V (r-Domain V) and beta2GPI from human plasma. On sodium dodecyl sulfate-polyacrylamide gel electrophoresis, r-Domain V was rapidly cleaved into a nicked form by plasmin, very slowly by factor Xa, but not by thrombin, tissue-type plasminogen activator, urokinase, and tissue factor/factor VIIa. The cleavage site of r-Domain V and beta2GPI by plasmin was proved to be Lys 317-Thr 318 by amino acid sequence analysis of the digest and of the C-terminal peptide isolated by high-performance liquid chromatography. The cleavage was completely inhibited by plasmin inhibitor (alpha2PI). The nicked form was demonstrated to show reduced affinity for CL with a dissociation constant of one order of magnitude larger than that of the intact beta2GPI. To determine whether the specific cleavage of beta2GPI by plasmin can occur also in plasma, human plasma was first acid-treated to inactivate alpha2PI and then incubated with urokinase. About 12% of beta2GPI in plasma was nicked when alpha2PI activity decreased to 80%. The nicked form was not generated in plasminogen-depleted plasma. These results suggest that plasmin can produce the nicked form of beta2GPI with the reduced ability to bind phospholipids in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9596664

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  Testing for and clinical significance of anticardiolipin antibodies.

Authors:  S W Reddel; S A Krilis
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

2.  β2-glycoprotein I and protection from anti-SSA/Ro60-associated cardiac manifestations of neonatal lupus.

Authors:  Joanne H Reed; Robert M Clancy; Anthony W Purcell; Mimi Y Kim; Tom P Gordon; Jill P Buyon
Journal:  J Immunol       Date:  2011-05-20       Impact factor: 5.422

3.  Studies on specific interaction of beta-2-glycoprotein I with HBsAg.

Authors:  Pu-Jun Gao; Yun-Feng Piao; Xiao-Dong Liu; Li-Ke Qu; Yang Shi; Xiao-Cong Wang; Han-Yi Yang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

4.  Plasmin-cleaved beta-2-glycoprotein 1 is an inhibitor of angiogenesis.

Authors:  Taro Sakai; Krishnakumar Balasubramanian; Sourindra Maiti; Jyotsna B Halder; Alan J Schroit
Journal:  Am J Pathol       Date:  2007-09-14       Impact factor: 4.307

5.  beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation.

Authors:  Chunya Bu; Lei Gao; Weidong Xie; Jainwei Zhang; Yuhong He; Guoping Cai; Keith R McCrae
Journal:  Arthritis Rheum       Date:  2009-02

6.  Beta 2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I.

Authors:  Tong Shi; G Michael Iverson; Jian C Qi; Keith A Cockerill; Matthew D Linnik; Pamela Konecny; Steven A Krilis
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-08       Impact factor: 11.205

7.  The J-elongated conformation of β2-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome.

Authors:  Eliza Ruben; William Planer; Mathivanan Chinnaraj; Zhiwei Chen; Xiaobing Zuo; Vittorio Pengo; Vincenzo De Filippis; Ravi K Alluri; Keith R McCrae; Paolo Macor; Francesco Tedesco; Nicola Pozzi
Journal:  J Biol Chem       Date:  2020-06-09       Impact factor: 5.157

8.  Beta2 glycoprotein I-derived therapeutic peptides induce sFlt-1 secretion to reduce melanoma vascularity and growth.

Authors:  Haley Smalley; Jennifer M Rowe; Fernando Nieto; Jazmin Zeledon; Kellyn Pollard; John M Tomich; Sherry D Fleming
Journal:  Cancer Lett       Date:  2020-09-04       Impact factor: 8.679

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.